ACTA ENDOCRINOLOGICA (BUC)

A certain degree of insulin resistance in patients with Gaucher disease type 1 (GD) under enzyme replacement therapy (ERT) was reported. Data on insulin sensitivity in treatment naïve patients are inconsistent. Objective. To analyse prospectively changes in parameters of insulin resistance under ERT and to estimate when they occur. Design. prospective, controlled study; three years follow-up. Patients and methods. 12 treatment naïve patients with GD type 1 (M/W 8/4), 29.5±12.9 years, without overweight, diagnosed enzymatically and by genotyping, without previous diabetes mellitus. Patients were evaluated before and every 6 months up to 3 years under ERT and compared at baseline and after 3 years with matched healthy controls. Fasting-glucose (FG), - insulin (FI), C-peptide, HOMA-IR, IRI, HOMA-B, blood count, hepatic and splenic volume, chitotriosidase, severity score index di Rocco (SSI) were assessed. Results. Baseline glycemic parameters did not differ from controls. FG increased from baseline after two years of ERT (+16.4%,p<0.010), FI (+40.3%,p=0.030), HOMA-IR (+61.2%,p=0.007) and IRI (+9.1%,p=0.010) after 18 months, HOMA-B after 2.5 years (+51%, p=0.015. After 3 years of ERT patients were more insulin resistant compared to controls (p<0.001): FG (96.0±6.2 vs. 73.2±6.4 mg/dL), FI (11.2±2.4 vs. 5.6±1.3 μU/L), HOMA-IR (2.7±0.6 vs. 1.0+0.3), IRI (3.02±0.10 vs. 2.62±0.13). FG, FI, HOMAIR, IRI, HOMA-B correlated with disease severity markers. Conclusions. This is the first controlled study which evaluates prospectively insulin resistance in GD patients, finding significant differences compared to baseline starting with 18 months ERT.

21-hydroxylase deficiency is with 90% the most frequent cause of congenital adrenal hyperplasia and is due to an inborn enzymatic defect of adrenal steroidogenesis inherited in an autosomal recessive manner. Here we report on the mutational spectrum of Romanian patients with classic\r\n21-hydroxylase deficiency and describe differences to other surrounding or Latin countries. The overall genotype-phenotype correlation was 87.8%. A new mutation P94L has been identified in a subgroup of patients with 11-?-hydroxylase deficiency. Furthermore, we address the issues of early alterations in bone mineral density and metabolism as well as early discrete alterations in lipid and carbohydrate metabolism with enhancement of the atherogenic small dense LDL-subfraction and emerging insulin resistance. The relationship of these discrete changes to treatment variables such as the mean and cumulative hydrocortisone dose stress once more the importance of an optimal glucocorticoid treatment with the lowest effective individual doses, to preclude the achievement of a suboptimal peak bone mass as well as the early appearance of traits of the metabolic syndrome.